Alboukadel Kassambara
Overview
Explore the profile of Alboukadel Kassambara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghiringhelli F, Bibeau F, Greillier L, Fumet J, Ilie A, Monville F, et al.
EBioMedicine
. 2023 May;
92:104633.
PMID: 37244159
Background: Anti-PD-1 and PD-L1 antibodies (mAbs) are approved immunotherapy agents to treat metastatic non-small cell lung cancer (NSCLC) patients. Only a minority of patients responds to these treatments and biomarkers...
2.
Moretto R, Rossini D, Catteau A, Antoniotti C, Giordano M, Boccaccino A, et al.
J Immunother Cancer
. 2023 Apr;
11(4).
PMID: 37085190
Background: Tumor immune cells influence the efficacy of immune-checkpoint inhibitors (ICIs) and many efforts aim at identifying features of tumor immune microenvironment able to predict benefit from ICIs in proficient...
3.
Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, et al.
Lancet Oncol
. 2022 May;
23(7):876-887.
PMID: 35636444
Background: Immune checkpoint inhibitors have not shown clinical benefit to patients with metastatic colorectal cancer who had proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumours in previous studies. Both...
4.
Boquet I, Kassambara A, Lui A, Tanner A, Latil M, Lovera Y, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267475
Adjunction of immune response into the TNM classification system improves the prediction of colon cancer (CC) prognosis. However, immune response measurements have not been used as robust biomarkers of pathology...
5.
RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
Alaterre E, Vikova V, Kassambara A, Bruyer A, Robert N, Requirand G, et al.
J Pers Med
. 2021 Oct;
11(10).
PMID: 34683129
Multiple myeloma (MM) is the second most frequent hematological cancer and is characterized by the clonal proliferation of malignant plasma cells. Genome-wide expression profiling (GEP) analysis with DNA microarrays has...
6.
Kassambara A, Herviou L, Ovejero S, Jourdan M, Thibaut C, Vikova V, et al.
Leukemia
. 2021 Apr;
35(5):1451-1462.
PMID: 33824465
Plasma cells (PCs) play an important role in the adaptive immune system through a continuous production of antibodies. We have demonstrated that PC differentiation can be modeled in vitro using...
7.
Devin J, Kassambara A, Bruyer A, Moreaux J, Bret C
J Clin Med
. 2019 Jul;
8(7).
PMID: 31336593
Multiparameter flow cytometry (MFC) is a fast and cost-effective technique to evaluate the expression of many lymphoid markers in mature B-cell neoplasms, including diffuse large B cell lymphoma (DLBCL), which...
8.
de Boussac H, Bruyer A, Jourdan M, Maes A, Robert N, Gourzones C, et al.
Haematologica
. 2019 Jul;
105(3):784-795.
PMID: 31289205
Multiple myeloma (MM) account for approximately 10% of hematological malignancies and is the second most common hematological disorder. Kinases inhibitors are widely used and their efficiency for the treatment of...
9.
Chatonnet F, Pignarre A, Serandour A, Caron G, Avner S, Robert N, et al.
Haematologica
. 2019 Jun;
105(3):774-783.
PMID: 31221779
Cell identity relies on the cross-talk between genetics and epigenetics and their impact on gene expression. Oxidation of 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) is the first step of an active...
10.
Vikova V, Jourdan M, Robert N, Requirand G, Boireau S, Bruyer A, et al.
Theranostics
. 2019 Feb;
9(2):540-553.
PMID: 30809292
Human multiple myeloma tumor cell lines (HMCLs) have been a cornerstone of research in multiple myeloma (MM) and have helped to shape our understanding of molecular processes that drive tumor...